JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crumb, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crumb, W. J., Jr.

Vol. 292, Issue 1, 261-264, January 2000

Loratadine Blockade of K+ Channels in Human Heart: Comparison with Terfenadine under Physiological Conditions

William J. Crumb, Jr.

Department of Pediatrics, Division of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana

Recently, there has been considerable attention focused on drugs that prolong the QT interval of the electrocardiogram, with the H1-receptor antagonist class of drugs figuring prominently. Albeit rare, incidences of QT prolongation and ventricular arrhythmias, in particular torsade de pointes, have been reported with the antihistamines astemizole and terfenadine and more recently with loratadine. The most likely mechanism for these drug-related arrhythmias is blockage of one or more ion channels involved in cardiac repolarization. Several studies have demonstrated block of multiple cardiac K+ channels by terfenadine, including Ito, Isus, IK1, and IKr or human ether-a-go-go-related gene (HERG). In contrast to terfenadine, previous studies have shown the antihistamine loratadine to be virtually free of cardiac ion channel-blocking effects. This disparity in the lack of any significant cardiac ion channel-blocking effect and the existence of numerous adverse cardiac event reports for loratadine prompted the comparison of the human cardiac K+ channel-blocking profile for loratadine and terfenadine under physiological conditions [37°C, holding potential (Vhold) = -75 mV] with the whole-cell patch-clamp method. Isolated human atrial myocytes were used to examine drug effects on Ito, Isus, and IK1, whereas HERG was studied in stably transfected HEK cells. In contrast to previous studies in nonhuman systems and/or under nonphysiological conditions, terfenadine (1 µM) had no effect on Ito, Isus, or IK1 at pacing rates up to 3 Hz. Similar results were found for 1 µM loratadine. However, both drugs potently blocked HERG current amplitude, with a mean IC50 of 173 nM for loratadine and 204 nM for terfenadine (pacing rate, 0.1 Hz). Neither drug exhibited any significant use-dependent blockage of HERG (pacing rates = 0.1-3 Hz). These results point to a similarity in the human cardiac K+ channel-blocking effects of loratadine and terfenadine and provide a possible mechanism for the arrhythmias associated with the use of either drug.


0022-3565/0/2921-0261$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J Biomol ScreenHome page
A. Finkel, A. Wittel, N. Yang, S. Handran, J. Hughes, and J. Costantin
Population Patch Clamp Improves Data Consistency and Success Rates in the Measurement of Ionic Currents
J Biomol Screen, August 1, 2006; 11(5): 488 - 496.
[Abstract] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
A. N. Katchman, J. Koerner, T. Tosaka, R. L. Woosley, and S. N. Ebert
Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1098 - 1106.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res, April 1, 2004; 62(1): 9 - 33.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Ekins, W. J. Crumb, R. D. Sarazan, J. H. Wikel, and S. A. Wrighton
Three-Dimensional Quantitative Structure-Activity Relationship for Inhibition of Human Ether-a-Go-Go-Related Gene Potassium Channel
J. Pharmacol. Exp. Ther., May 1, 2002; 301(2): 427 - 434.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
I. Cavero and W. Crumb
Native and cloned ion channels from human heart: laboratory models for evaluating the cardiac safety of new drugs
Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K53 - K63.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.